Literature DB >> 33078236

Systematic Review and Meta-analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.

Gabriel M Knight1, Abhinav Talwar1, Riad Salem2,3, Samdeep Mouli1,4.   

Abstract

PURPOSE: To report a comparative systematic review and meta-analysis of prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) for the management of benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: A multi-database search for relevant literature was conducted on 15 July 2020 to include studies published on or before that date. Search terms used were: (prostate embolization OR prostatic embolization OR prostate embolization OR prostatic embolization) AND (prostatic hyperplasia OR prostatic obstruction). Risk of bias was assessed using Cochrane Collaboration and ROBINS-I criteria. Random-effects meta-analysis was performed using RevMan 5.3.
RESULTS: Six studies with 598 patients were included. TURP was associated with significantly more improvement in maximum urinary flow rate (Qmax) (mean difference = 5.02 mL/s; 95% CI [2.66,7.38]; p < 0.0001; I2 = 89%), prostate volume (mean difference = 15.59 mL; 95% CI [7.93,23.25]; p < 0.00001; I2 = 88%), and prostate-specific antigen (PSA) (mean difference = 1.02 ng/mL; 95% CI [0.14,1.89]; p = 0.02; I2 = 71%) compared to PAE. No significant difference between PAE and TURP was observed for changes in International Prostate Symptoms Score (IPSS), IPSS quality of life (IPSS-QoL), International Index of Erectile Function (IIEF-5), and post-void residual (PVR). PAE was associated with fewer adverse events (AEs) (39.0% vs. 77.7%; p < 0.00001) and shorter hospitalization times (mean difference = -1.94 days; p < 0.00001), but longer procedural times (mean difference = 51.43 min; p = 0.004).
CONCLUSION: Subjective symptom improvement was equivalent between TURP and PAE. While TURP demonstrated larger improvements for some objective parameters, PAE was associated with fewer AEs and shorter hospitalization times. LEVEL OF EVIDENCE II: Level 2a, Systematic Review.

Entities:  

Mesh:

Year:  2020        PMID: 33078236     DOI: 10.1007/s00270-020-02657-5

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  1 in total

Review 1.  Evolving and investigational therapies for benign prostatic hyperplasia.

Authors:  Shiva Madhwan Nair; Marie Adrianne Pimentel; Peter J Gilling
Journal:  Can J Urol       Date:  2015-10       Impact factor: 1.344

  1 in total
  8 in total

1.  Analgesic Effects of Dexmedetomidine Combined with Spinal and Epidural Anesthesia Nursing on Prostate Hyperplasia Patients after Transurethral Resection of Prostate by Intelligent Algorithm-Based Magnetic Resonance Imaging.

Authors:  Xiaoyan Zhang; Manyun Bo; Rong Zeng; Liping Zou; Yanfang He
Journal:  Comput Math Methods Med       Date:  2022-05-21       Impact factor: 2.809

2.  Commentary on the Article "Systematic Review and Meta-Analysis Comparing Prostatic Artery Embolisation to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia".

Authors:  Dominik Abt; Valentin Zumstein; Lukas Hechelhammer
Journal:  Cardiovasc Intervent Radiol       Date:  2020-11-17       Impact factor: 2.740

Review 3.  Minimally Invasive Therapies for Benign Prostatic Obstruction: A Review of Currently Available Techniques Including Prostatic Artery Embolization, Water Vapor Thermal Therapy, Prostatic Urethral Lift, Temporary Implantable Nitinol Device and Aquablation.

Authors:  Tiago Bilhim; Patrick Betschart; Pavel Lyatoshinsky; Gautier Müllhaupt; Dominik Abt
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-18       Impact factor: 2.740

Review 4.  Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.

Authors:  Juan Va Franco; Jae Hung Jung; Mari Imamura; Michael Borofsky; Muhammad Imran Omar; Camila Micaela Escobar Liquitay; Shamar Young; Jafar Golzarian; Areti Angeliki Veroniki; Luis Garegnani; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-07-15

5.  An Updated Meta-Analysis of the Efficacy and Safety of Prostatic Artery Embolization vs. Transurethral Resection of the Prostate in the Treatment of Benign Prostatic Hyperplasia.

Authors:  Zhunan Xu; Zhongbao Zhou; Yingmei Mu; Tong Cai; Zhenli Gao; Lingling Liu
Journal:  Front Surg       Date:  2021-12-15

6.  Prostatic Artery Embolization for Lower Urinary Tract Symptoms via Transradial Versus Transfemoral Artery Access: Single-Center Technical Outcomes.

Authors:  Ryun Gil; Dong Jae Shim; Doyoung Kim; Dong Hwan Lee; Jung Jun Kim; Jung Whee Lee
Journal:  Korean J Radiol       Date:  2022-05       Impact factor: 3.500

7.  Risk Factors of Urinary Pathogenic Bacteria Infection after Benign Prostatic Hyperplasia Surgery and Curative Effect Analysis of Shuangdong Capsule Intervention.

Authors:  Bing Xu; Ming Liu; Yonghui Liu; Jianhong Zuo
Journal:  Emerg Med Int       Date:  2022-09-08       Impact factor: 1.621

8.  Prostatic Artery Embolization (PAE) Using Polyethylene Glycol Microspheres: Safety and Efficacy in 81 Patients.

Authors:  Iñigo Insausti; Arkaitz Galbete; Vanesa Lucas-Cava; Ana Sáez de Ocáriz; Saioa Solchaga; Raquel Monreal; Antonio Martínez de la Cuesta; Raquel Alfaro; Fei Sun; Manuel Montesino; Fermin Urtasun; José Ignacio Bilbao Jaureguízar
Journal:  Cardiovasc Intervent Radiol       Date:  2022-06-02       Impact factor: 2.797

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.